News

March 5, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the ... Read more

March 4, 2020March 4, 2020

Panel Recommends European Approval of Entyvio At-Home Injection

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of a subcutaneous (under-the-skin) injection of Entyvio (Vedolizumab), the gut-selective maintenance therapy ... Read more

March 2, 2020March 2, 2020

Remsima in New Injection Form Shows Safety and Efficacy in Trial

News

A new formulation of CT-P13, a biosimilar of Remicade (infliximab), given as an under-the-skin injection is as safe and effective for people with active Crohn’s disease (CD) and ulcerative colitis (UC) ... Read more

February 26, 2020February 26, 2020

New Entyvio Formulation – Given as Injection at Home – Leads to Crohn’s Remission After One Year, Takeda Announces

News

Maintenance therapy with Entyvio‘s new formulation as a subcutaneous, or under-the-skin injection (SC) led more people with moderate-to-severe, active Crohn’s disease (CD) to achieve clinical remission after one year, ... Read more

February 24, 2020February 24, 2020

Stelara Leads to High Clinical Response, Remission in Severely Active Crohn’s, Phase 3 Study Shows

News

Almost 80% of patients with severely active Crohn’s disease (CD) responded to treatment with Stelara (ustekinumab) and two-thirds achieved clinical remission, according to 16-week results from a Phase 3 clinical ... Read more

February 19, 2020February 19, 2020

Oral Brilacidin Found to be Well-tolerated in Healthy Volunteers With Delivery Localized to the Colon, Trial Shows

News

Delayed-release oral tablets of brilacidin for ulcerative colitis (UC) was found delivered and dispersed into the colon, and was well-tolerated in healthy volunteers in a Phase 1 trial, announced ... Read more

February 17, 2020February 17, 2020

CT-SCOUT App Markedly Improves Enrollment Rates for IBD Trials, Developer Says

News

Patient recruitment rates in recent international inflammatory bowel disease (IBD) clinical trials increased markedly when the CT-SCOUT digital solution was used, the technology’s developer announced. The French start-up company Clinical ... Read more

February 14, 2020February 14, 2020

Crohn’s & Colitis Foundation Helps Advance Tissium’s Platform to Promote Tissue Healing

News

The Crohn’s & Colitis Foundation has provided funding to life science company Tissium to address the unmet medical needs of patients with Crohn’s disease, specifically to advance technology that ... Read more

February 12, 2020February 12, 2020

One in Six IBD Patients Meet Criteria for Substance Use Disorder (SUD), Study Suggests

News

One in six patients with inflammatory bowel disease (IBD) experience a substance use disorder (SUD), or drug or alcohol addiction, a study suggests. In particular, people with IBD with ... Read more

February 10, 2020February 10, 2020

Crohn’s & Colitis Foundation, Genedata Collaborate on Precision Medicine

News

Genedata and the Crohn’s & Colitis Foundation completed a project aimed at advancing precision care for Crohn’s disease patients. Genedata, a biopharmaceutical research and development software company, worked with ... Read more